Home › Trials › NCT06419413

Understanding asthma characteristics and outcomes in the Chinese population

A Transnational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population

Observational AstraZeneca · NCT06419413

This study looks at the different types of asthma in people in China to see how their symptoms and treatments vary, with the goal of helping create better, personalized care for them.

Quick facts

Study typeObservational
Enrollment355 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorAstraZeneca Industry-sponsored
Locations21 sites (Chengdu, Sichuan and 20 other locations)
Trial IDNCT06419413 on ClinicalTrials.gov

What this trial studies

This observational study aims to describe the clinical characteristics, treatment patterns, and biomarkers of asthma patients in China. It focuses on identifying different phenotypes and endotypes associated with varying outcomes in these patients. By analyzing data from individuals aged 18 to 75 with a physician-diagnosed asthma, the study seeks to support the future development of personalized treatment strategies tailored to the Chinese population.

Who should consider this trial

Good fit: Ideal candidates for this study are individuals aged 18 to 75 with a physician-diagnosed asthma for at least three months.

Not a fit: Patients with a history of substance abuse, pregnant individuals, or those with terminal diseases may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more effective and personalized asthma treatments for patients in China.

How similar studies have performed: Other studies have shown success in identifying asthma phenotypes and endotypes, suggesting that this approach may yield valuable insights.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age 18 to 75 years of age
* acceptable FEV1 (according to ATS and ERS)
* compliance with study procedures All Asthma Cohorts
* physician diagnosed Asthma greater or equal to 3 months prior to screening visit

Exclusion Criteria:

* history of alcohol or drug abuse within the past year
* pregnant at time of an assessment
* has an altered mental status at the time of informed consent
* receipt marketed or investigational biologic(s) within 3 months or 5 half-lives prior to visit 1, whichever is longer
* history or current upper or lower respiratory infection or symptoms within 2 weeks of baseline assessments
* terminal diseases and/or organ failure or participants otherwise considered not appropriate for the study participation
* Receipt LTRAs or 5-lipoxygenase (5-LO) inhibitors (eg zileuton and montelukast) within 1 month or 5 half-lives prior to baseline, whichever is longer.

Where this trial is running

Chengdu, Sichuan and 20 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Asthma
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.